

Appendix 4E

BioTech Capital Limited

ABN 45 091 979 172

Preliminary Final Report for the Year Ended 30 June 2013

1 Reporting period: year ended 30 June 2013 (previous period: year ended 30 June 2012)

2 **Results for announcement to the Market:**

2.1 Revenue from continuing operations	\$37,712
- percentage change from previous period: up	-28.27% (previous revenue of \$52,577)
2.2 Profit/(Loss) from continuing operations, after tax attributable to members:	-\$501,748
- percentage change from previous period: up	-73.03% (previous loss of \$1,860,167)
2.3 Net Profit/(Loss) from continuing operations, attributable to members:	-\$501,748
- percentage change from previous period: up	-73.03% (previous loss of \$1,860,167)
2.4 Dividend:	It is not proposed to pay a dividend
2.5 Dividend record date:	Not applicable
2.6 Further explanation of the figures contained in 2.1 to 2.3 is contained in the attached Financial Report	

3 A statement of profit or loss and other comprehensive income for the period, together with notes to the statement, prepared in accordance with AASB 101, is contained in the attached Financial Report.

4 A statement of financial position at the balance date, together with notes to the statement, is contained in the attached Financial Report.

5 A statement of cash flows for the period, together with notes to the statement, is contained in the attached Financial Report.

6 On 16 October 2012, the directors declared an unfranked dividend of 1 cent per share to holders of fully paid ordinary shares in respect of the financial year ended 30 June 2013. The total dividend of \$745,540 is reflected in the Financial Report.

7 There are no dividend or distribution reinvestment plans in operation.

8 A statement of retained earnings showing movements is contained in the attached Financial Report.

9 Net tangible assets per share Current and Previous period: **\$0.04** **\$0.06**

10 The company has neither gained nor lost control of any entities during the period.

11 The company has no associate or joint venture relationships with any entities.

12 All significant information needed to enable an investor to make an informed assessment of the company's financial performance is contained in this appendix and the attached Financial Report.

13 The company is an Australian company registered under the Pooled Development Funds Act, 1992.

Appendix 4E

cont.... Page 2/2

BioTech Capital Limited

Preliminary Final Report for the Year Ended 30 June 2013

- 14 A commentary on the results for the period is contained in the attached Financial Report, including:
- 14.1 earnings per share and the nature of any dilution aspects;
 - 14.2 returns to shareholders including any distributions and buy backs;
 - 14.3 significant features of operating performance (see below);
 - 14.4 results of any segments that are significant to an understanding of the business as a whole;
 - 14.5 discussion of any trends in performance;
 - 14.6 Any other factors which have affected results in the period, or are likely to affect results in the future.
- 15 The information contained in this appendix and the attached Financial Report are based on accounts which are in the process of being audited.
- 14.3 During the year ended 30 June 2013, a provision for loss on unlisted investments of \$379,053 was recorded in the statement of comprehensive income.